Ubs Group Ag Inventiva S.A. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IVA
# of Institutions
8Shares Held
4.85MCall Options Held
0Put Options Held
0-
Yiheng Capital Management, L.P. San Francisco, CA2.64MShares$7.09 Million0.64% of portfolio
-
Nea Management Company, LLC Timonium, MD1.46MShares$3.92 Million0.41% of portfolio
-
Bvf Inc San Francisco, CA686KShares$1.84 Million0.06% of portfolio
-
Commonwealth Equity Services, LLC39.7KShares$106,4890.0% of portfolio
-
Morgan Stanley New York, NY1.7KShares$4,5560.0% of portfolio
About Inventiva S.A.
- Ticker IVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,134,200
- Market Cap $113M
- Description
- Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...